Polymer-drug conjugates: Recent development in clinical oncology

Advanced Drug Delivery Reviews

Volumn 60, Issue 8, 2008, Pages 886-898

  Li, Chun ^a   Wallace, Sidney ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anticancer drugs; Nanocarriers; Paclitaxel; PG TXL; Polymer drug conjugates

Indexed keywords

DISEASES; DRUG THERAPY; ONCOLOGY; ORGANIC POLYMERS;

ANTICANCER DRUGS; NANOCARRIERS; PACLITAXEL; POLYMER-DRUG CONJUGATES;

DRUG PRODUCTS;

1,2 DIAMINOCYCLOHEXANE; ANTINEOPLASTIC AGENT; AP 5346; BETA CYCLODEXTRIN; CARBOPLATIN; CISPLATIN; CREMOPHOR; CT 2106; DE 310; DOCETAXEL; DOXORUBICIN; DRUG CARRIER; EZN 2208; FCE 28068; FCE 28069; GEMCITABINE; IT 101; MACROGOL; N (2 HYDROXYPROPYL)METHACRYLAMIDE; NAVELBINE; NK 911; PACLITAXEL; PACLITAXEL POLIGLUMEX; PEGAMOTECAN; PNU 166148; PNU 166945; POLYGLUTAMIC ACID; POLYMER; POLYMETHACRYLIC ACID; PROLINDAC; UNINDEXED DRUG;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLADDER DISEASE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG UPTAKE; DYSURIA; ESOPHAGITIS; ESOPHAGUS CANCER; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; GASTRITIS; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; LIVER CELL CARCINOMA; LIVER TOXICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; MELANOMA; MOLECULAR WEIGHT; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; ONCOLOGY; OVARY CANCER; PANCREAS CANCER; PARTIAL THROMBOPLASTIN TIME; PERITONEUM CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; REVIEW; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; VEIN OCCLUSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; PACLITAXEL; POLYGLUTAMIC ACID; POLYMERS;

EID: 42749091133     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.11.009     Document Type: Review

References (71)

1. Ringsdorf H. Structure and properties of pharmacologically active polymers. J. Polym. Sci. Symp. 51 (1975) 135-153
2. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release 65 (2000) 271-284
3. Li C. Poly(l-glutamic acid)-anticancer drug conjugates. Adv. Drug Deliv. Rev. 54 (2002) 695-713
4. Maeda H., and Kono T. Neocarzinostatin: The Past, Present, and Future of an Anticancer Drug (1997), Springer, Berlin 227-267
5. Graham L.M. PEGASPARAGINASE: a review of clinical studies. Adv. Drug Deliv. Rev. 10 (2003) 1293-1302
6. Wang Y.S., Youngster S., Grace M., Bausch J., Bordens R., and Wyss D.F. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Deliv. Rev. 54 (2002) 547-570
7. Kinstler O., Molineux G., Treuheit M., Ladd D., and Gegg C. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 54 (2002) 477-485
8. Harris J.M., and Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2 (2003) 214-221
9. Greenwald R.B. PEG drugs: an overview. J. Control. Release 74 (2001) 159-171
10. Horwitz S.B. Taxol (Paclitaxel): mechanisms of action. Ann. Oncol. 5 (1994) S3-S6
11. Allouache D., Gawande S.R., Tubiana-Hulin M., Tubiana-Mathieu N., Piperno-Neumann S., Mefti F., Bozec L., and Genot J.Y. First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study. BMC Cancer 5 (2005) 151
12. Li C., Yu D.F., Newman R.A., Cabral F., Stephens L.C., Hunter N., Milas L., and Wallace S. Complete regression of well-established tumors using a novel water-soluble poly(l-glutamic acid)-paclitaxel conjugate. Cancer Res. 58 (1998) 2404-2409
13. Li C., Price J.E., Milas L., Hunter N.R., Ke S., Yu D.F., Charnsangavej C., and Wallace S. Antitumor activity of poly(l-glutamic acid)-paclitaxel on syngeneic and xenografted tumors. Clin. Cancer Res. 5 (1999) 891-897
14. Auzenne E., Donato N.J., Li C., Leroux E., Price R.E., Farquhar D., and Klostergaard J. Superior therapeutic profile of poly-l-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma. Clin. Cancer Res. 8 (2002) 573-581
15. Multani A.S., Li C., Ozen M., Imam A.S., Wallace S., and Pathak S. Cell-killing by paclitaxel in a metastatic murine melanoma cell line is mediated by extensive telomere erosion with no decrease in telomerase activity. Oncol. Rep. 6 (1999) 39-44
16. Oldham E.A., Li C., Ke S., Wallace S., and Huang P. Comparison of action of paclitaxel and poly(l-glutamic acid)-paclitaxel conjugate in human breast cancer cells. Int. J. Oncol. 16 (2000) 125-132
17. Li C., Newman R.A., Wu Q.P., Ke S., Chen W., Hutto T., Kan Z., Brannan M.D., Charnsangavej C., and Wallace S. Biodistribution of paclitaxel and poly(l-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother. Pharmacol. 46 (2000) 416-422
18. Singer J.W., Shaffer S., Baker B., Bernareggi A., Stromatt S., Nienstedt D., and Besman M. Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane. Anticancer Drugs 16 (2005) 243-254
19. Shaffer S., Baker-Lee C., Kennedy J., Lai M., de Vries P., Buhler K., and Singer J. In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases. Cancer Chemother Pharmacol 59 (2007) 537-548
20. Jackson E.F., Esparza-Coss E., Wen X., Ng C.S., Daniel S.L., Price R.E., Rivera B., Charnsangavej C., Gelovani J.G., and Li C. Magnetic resonance imaging of therapy-induced necrosis using gadolinium-chelated polyglutamic acids. Int. J. Radiat. Oncol. Biol. Phys. 68 (2007) 830-838
21. Chipman S., Rosler R., Bonham L., Nudelman E., and Singer J. Energy dependent uptake of paclitaxel poliglumex by human NSCLC tumor and murine macrophase-like cell lines. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Prague, Czech Republic, November 7-10, 2006, Abstract #643 (2006)
22. Fornasier M., Bergottini R., Radaelli E., Cavagnoli R., Di Giovine S., De Feudis P., Chipman S., Pezzoni G., and Singer J. Paclitaxel poliglumex cellular uptake by normal tissues and human tumor xenograft: an IHC study in nude mice. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Prague, Czech Republic, November 7-10, 2006, Abstract #637 (2006)
23. Jain R.K. Barriers to drug delivery in solid tumors. Sci. Am. 271 (1994) 58-65
24. Lu D., Wientjes M.G., Lu Z., and Au J.L. Tumor priming enhances delivery and efficacy of nanomedicines. J. Pharmacol. Exp. Ther. 322 (2007) 80-88
25. Melancon M.P., Wang W., Wang Y., Shao R., Ji X., Gelovani J.G., and Li C. A novel method for imaging in vivo degradation of poly(l-glutamic acid), a biodegradable drug carrier. Pharm. Res. 24 (2007) 1217-1224
26. Roshy S., Sloane B.F., and Moin K. Pericellular cathepsin B and malignant progression. Cancer Metastasis Rev. 22 (2003) 271-286
27. Todd R., Sludden J., Boddy A.V., Griffin M.J., Robson L., Cassidy J., Bissett D., Main M., Brannan M.D., Elliott S., Fishwick K., Verrill M., and Calvert H. Phase I and pharmacological study of CT-2103, a poly(l-glutamic acid)-paclitaxel conjugate. ASCO vol. 439 (2001)
28. Bernareggi A., Oldham F., and Barone C. XYOTAX (paclitaxel poliglumex; CT-2103): pharmacokinetic evidence for an enhanced permeability and retention effect. 29th Congress of the European Society for Medical Oncology (2004)
29. Boddy A.V., Plummer E.R., Todd R., Sludden J., Griffin M., Robson L., Cassidy J., Bissett D., Bernareggi A., Verrill M.W., and Calvert A.H. A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules. Clin. Cancer Res. 11 (2005) 7834-7840
30. Nemunaitis J., Cunningham C., Senzer N., Gray M., Oldham F., Pippen J., Mennel R., and Eisenfeld A. Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors. Cancer Investig. 23 (2005) 671-676
31. Dipetrillo T., Milas L., Evans D., Akerman P., Ng T., Miner T., Cruff D., Chauhan B., Iannitti D., Harrington D., and Safran H. Paclitaxel poliglumex (PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer: a phase I study. Am. J. Clin. Oncol. 29 (2006) 376-379
32. Sabbatini P., Aghajanian C., Dizon D., Anderson S., Dupont J., Brown J.V., Peters W.A., Jacobs A., Mehdi A., Rivkin S., Eisenfeld A.J., and Spriggs D. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J. Clin. Oncol. 22 (2004) 4523-4531
33. Lin N.U., Parker L.M., Come S.E., Burstein H.J., Haldoupis M., Ryabin N., Gelman R., Winer E.P., and Shulman L.N. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest. New Drugs 25 (2007) 369-375
34. Amato R.J., Khan M., and M.T. Phase II study of paclitaxel poliglumex (PPX) for androgen independent prostate cancer (AIPC). American Society of Clinical Oncology (ASCO), 2007 Prostate Cancer Symposium, Abstract 243 (2007)
35. Bonomi P. Paclitaxel poliglumex (PPX, CT-2103): macromolecular medicine for advanced non-small-cell lung cancer. Expert. Rev. Anticancer Ther. 7 (2007) 415-422
36. Ross H., Bonomi P., Langer C., O'Brien M., O'Byrne K., Paz-Ares L., Sandler A., Socinski M., Oldham F., and Singer J. Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemo-naïve pts with advanced NSCLC and poor performance status (PS2). J. Clin. Oncol. 24 (2006) Abstract #7039
37. Albain K.S., Belani C.P., Bonomi P., O'Byrne K.J., Schiller J.H., and Socinski M. PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin. Lung Cancer 7 (2006) 417-419
38. Li C., Ke S., Wu Q.-P., Tansey W., Hunter N., Buchmiller L.M., Milas L., Charnsangavej C., and Wallace S. Potentiation of ovarian OCa-1 tumor radioresponse by poly (l-glutamic acid)-paclitaxel conjugate. Int. J. Radiat. Oncol. Biol. Phys. 48 (2000) 1119-1126
39. Li C., Ke S., Wu Q.-P., Tansey W., Hunter N., Buchmiller L.M., Milas L., Charnsangavej C., and Wallace S. Tumor irradiation enhances the tumor-specific distribution of poly(l-glutamic acid)-conjugated paclitaxel and its antitumor efficacy. Clin. Cancer Res. 6 (2000) 2829-2834
40. Ke S., Milas L., Charnsangavej C., Wallace S., and Li C. Potentiation of radioresponse by polymer-drug conjugates. J. Control. Release 74 (2001) 237-242
41. Milas L., Mason K.A., Hunter N., Li C., and Wallace S. Poly(l-glutamic acid)-paclitaxel conjugate is a potent enhancer of tumor radiocurability. Int. J. Radiat. Oncol. Biol. Phys. 55 (2003) 707-712
42. Tishler R.B. Polymer-conjugated paclitaxel as a radiosensitizing agent-a big step forward for combined modality therapy?. Int. J. Radiat. Oncol. Biol. Phys. 55 (2003) 563-564
43. Duncan R., Cable H.C., Lloyd J.B., Rejmanova P., and Kopecek J. Degradation of side-chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases. Biosci. Rep. 2 (1982) 1041-1046
44. Duncan R., Rejmanova P., Kopecek J., and Lloyd J.B. Pinocytic uptake and intracellular degradation of N-(2-hydroxypropyl)methacrylamide copolymers. A potential drug delivery system. Biochim. Biophys. Acta 678 (1981) 143-150
45. Seymour L.W., Ulbrich K., Steyger P.S., Brereton M., Subr V., Strohalm J., and Duncan R. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer 70 (1994) 636-641
46. Minko T., Kopeckova P., and Kopecek J. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int. J. Cancer 86 (2000) 108-117
47. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., and Cassidy J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-Hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res. 5 (1999) 83-94
48. Bilim V. Technology evaluation: PK1, Pfizer/Cancer Research UK. Curr. Opin. Mol. Ther. 5 (2003) 326-330
49. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs 3 (1992) 175-210
50. Duncan R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2 (2003) 347-360
51. Duncan R., Vicent M.J., Greco F., and Nicholson R.I. Polymer-drug conjugates: towards a novel approach for the treatment of endocrine-related cancer. Endocr. Relat. Cancer 12 Suppl. 1 (2005) S189-S199
52. Seymour L.W., Ferry D.R., Anderson D., Hesslewood S., Julyan P.J., Poyner R., Doran J., Young A.M., Burtles S., and Kerr D.J. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 20 (2002) 1668-1676
53. Bissett D., Cassidy J., de Bono J.S., Muirhead F., Main M., Robson L., Fraier D., Magne M.L., Pellizzoni C., Porro M.G., Spinelli R., Speed W., and Twelves C. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br. J. Cancer 91 (2004) 50-55
54. Schoemaker N.E., van Kesteren C., Rosing H., Jansen S., Swart M., Lieverst J., Fraier D., Breda M., Pellizzoni C., Spinelli R., Grazia Porro M., Beijnen J.H., Schellens J.H., and ten Bokkel Huinink W.W. A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin. Br. J. Cancer 87 (2002) 608-614
55. Meerum Terwogt J.M., ten Bokkel Huinink W.W., Schellens J.H., Schot M., Mandjes I.A., Zurlo M.G., Rocchetti M., Rosing H., Koopman F.J., and Beijnen J.H. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 12 (2001) 315-323
56. Campone M., Rademaker-Lakhai J.M., Bennouna J., Howell S.B., Nowotnik D.P., Beijnen J.H., and Schellens J.H. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemother. Pharmacol. 60 (2007) 523-533
57. Greenwald R.B., Pendri A., Conover C., Gilbert C., Yang R., and Xia J. Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms. J. Med. Chem. 39 (1996) 1938-1940
58. Posey III J.A., Saif M.W., Carlisle R., Goetz A., Rizzo J., Stevenson S., Rudoltz M.S., Kwiatek J., Simmons P., Rowinsky E.K., Takimoto C.H., and Tolcher A.W. Phase 1 study of weekly olyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas. Clin. Cancer Res. 11 (2005) 7866-7871
59. Sapra P., Mehlig M., Malaby J., Kraft P., Zhang Z., Longley C., Zhao H., Rubio B., Wu D., Greenberger L.M., and Horak I.D. EZN-2208, a novel polyethyleneglycol-SN38 conjugate, has potent antitumor activity in a panel of human tumor xenografts. American Association of Cancer Research Annual Meeting Poster No. 1494 (2007)
60. Nakanishi T., Fukushima S., Okamoto K., Suzuki M., Matsumura Y., Yokoyama M., Okano T., Sakurai Y., and Kataoka K. Development of the polymer micelle carrier system for doxorubicin. J. Control. Release 74 (2001) 295-302
61. Schluep T., Cheng J., Khin K., and Davis M. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother. Pharmacol. 57 (2006) 654-662
62. Schluep T., Hwang J., Cheng J., Heidel J.D., Bartlett D.W., Hollister B., and Davis M.E. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin. Cancer Res. 12 (2006) 1606-1614
63. Inoue K., Kumazawa E., Kuga H., Susaki H., Masubuchi N., and Kajimura T. CM-dextran-polyalcohol-camptothecin conjugate: DE-310 with a novel carrier system and its preclinical data. Adv. Exp. Med. Biol. 519 (2003) 145-153
64. Soepenberg O., de Jonge M.J.A., Sparreboom A., de Bruin P., Eskens F.A.L.M., de Heus G., Wanders J., Cheverton P., Ducharme M.P., and Verweij J. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin. Cancer Res. 11 (2005) 703-711
65. Zou Y., Wu Q.P., Tansey W., Chow D., Hung M.C., Charnsangavej C., Wallace S., and Li C. Effectiveness of water soluble poly(l-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice. Int. J. Oncol. 18 (2001) 331-336
66. Singer J.W., De Vries P., Bhatt R., Tulinsky J., Klein P., Li C., Milas L., Lewis R.A., and Wallace S. Conjugation of camptothecins to poly-(l-glutamic acid). Ann. N.Y. Acad. Sci. 922 (2000) 136-150
67. Singer J.W., Bhatt R., Tulinsky J., Buhler K.R., Heasley E., Klein P., and de Vries P. Water-soluble poly-(l-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo. J. Control. Release 74 (2001) 243-247
68. Bhatt R., de Vries P., Tulinsky J., Bellamy G., Baker B., Singer J.W., and Klein P. Synthesis and in vivo antitumor activity of poly(l-glutamic acid) conjugates of 20S-camptothecin. J. Med. Chem. 46 (2003) 190-193
69. Springett G.M., Takimoto C., McNamara M., Doroshow J.H., Syed S., Eastham E., Spriggs D., Pezzulli S., Michelson G., and D.J. Phase I study of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. 2004 ASCO Annual Meeting Proceedings. Journal of Clinical Oncology vol. 22 (2004) Abstract #3127
70. McNamara M.V., Doroshow J.H., Dupont J., Spriggs D., Eastham E., Pezzulli S., Syed S., Bernareggi A., and Takimoto C. Preliminary pharmacokinetics of CT-2106 (polyglutamate camptothecin) in patients with advanced malignancies. J. Clin. Oncol. (Meeting Abstracts) 22 (2004) 2073
71. Homsi J., Simon G.R., Garrett C.R., Springett G., De Conti R., Chiappori A.A., Munster P.N., Burton M.K., Stromatt S., Allievi C., Angiuli P., Eisenfeld A., Sullivan D.M., and Daud A.I. Phase I trial of poly-l-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin. Cancer Res. 13 (2007) 5855-5861